

Title (en)
USE OF MHC-II BINDING AND/OR MHC-II MIMICKING MOLECULES FOR THE PREVENTION AND/OR TREATMENT OF INFLAMMATORY DISEASES

Title (de)
VERWENDUNG VON MHC-II BINDEDEN UND/ODER IMITIERENDEN MOLEKÜLEN ZUR VORBEUGUNG UND/ODER BEHANDLUNG VON ENTZÜNDLICHEN KRANKHEITEN

Title (fr)
UTILISATION DE MOLECULES SE FIXANT A CNH-II ET/OU SIMULANT CNH-II DANS LA PREVENTION ET/OU LE TRAITEMENT DES ETATS INFLAMMATOIRES

Publication
EP 0800534 A2 19971015 (EN)

Application
EP 95942207 A 19951227

Priority

- EP 95942207 A 19951227
- EP 9505164 W 19951227
- EP 94203755 A 19941223

Abstract (en)
[origin: WO9620215A2] The invention relates to MHC-II binding and/or MHC-II mimicking molecules for use in interfering in the interaction between an activation stimulus for MHC-II bearing cells, such as phagocytes and cell-bound MHC-II molecules, in the interaction between lipopolysaccharide (LPS) or LPS in a complex with other molecules, such as CD14 and LBP, and cell-bound MHC-II molecules, or in the interaction between products from Gram-positive bacteria or complexes of products from Gram-positive bacteria with molecules such as CD14, and cell-bound MHC-II molecules. The MHC-II binding molecule may be any anti-MHC-II antibody or fragment thereof, or any molecule derived from such an antibody such as humanized, bispecific or other engineered molecules and the like. The MHC-II binding molecule may be selected from the group consisting of CD14, fragments thereof, modified versions thereof, or peptides having MHC-II binding properties.

IPC 1-7
C07K 14/74; **C07K 16/28**; **A61K 39/395**; **A61K 38/17**

IPC 8 full level
C12N 5/10 (2006.01); **A61K 38/00** (2006.01); **A61K 38/17** (2006.01); **A61K 39/395** (2006.01); **A61P 1/00** (2006.01); **A61P 3/08** (2006.01); **A61P 9/10** (2006.01); **A61P 17/00** (2006.01); **A61P 25/00** (2006.01); **A61P 29/00** (2006.01); **A61P 31/12** (2006.01); **A61P 35/00** (2006.01); **A61P 37/00** (2006.01); **A61P 37/08** (2006.01); **C07K 14/705** (2006.01); **C07K 14/74** (2006.01); **C07K 16/28** (2006.01); **A61K 39/385** (2006.01)

CPC (source: EP)
A61P 1/00 (2017.12); **A61P 3/08** (2017.12); **A61P 9/10** (2017.12); **A61P 17/00** (2017.12); **A61P 25/00** (2017.12); **A61P 29/00** (2017.12); **A61P 31/12** (2017.12); **A61P 35/00** (2017.12); **A61P 37/00** (2017.12); **A61P 37/08** (2017.12); **C07K 14/70539** (2013.01); **C07K 16/2833** (2013.01); **A61K 38/00** (2013.01)

Citation (search report)
See references of WO 9620215A2

Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 9620215 A2 19960704; **WO 9620215 A3 19961010**; AU 4347696 A 19960719; BR 9510554 A 19990629; CA 2208233 A1 19960704; CN 1171117 A 19980121; CZ 186897 A3 19980318; EP 0800534 A2 19971015; HU T77468 A 19980528; JP H10511652 A 19981110; PL 320922 A1 19971110; SK 80697 A3 19971210

DOCDB simple family (application)
EP 9505164 W 19951227; AU 4347696 A 19951227; BR 9510554 A 19951227; CA 2208233 A 19951227; CN 95196985 A 19951227; CZ 186897 A 19951227; EP 95942207 A 19951227; HU 9800269 A 19951227; JP 52022096 A 19951227; PL 32092295 A 19951227; SK 80697 A 19951227